CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.
APA
Khan F, Chandra MB, et al. (2026). CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.. Journal of the National Comprehensive Cancer Network : JNCCN, 24(3.5). https://doi.org/10.6004/jnccn.2025.7384
MLA
Khan F, et al.. "CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 24, no. 3.5, 2026.
PMID
41991094
같은 제1저자의 인용 많은 논문 (5)
- EPR26-173: Weekend Admissions and Clinical Outcomes in Pancreatic Cancer: Evidence From the National Inpatient Sample.
- Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis.
- Enteroblastic and Hepatoid Colorectal Carcinomas are Aggressive Cancers With a Distinctive Immunophenotype, While Clear Cell Carcinoma Appears to Represent Clear Cell Change in Conventional Colorectal Cancer.
- Bioinformatics Approaches in Noncoding RNAs Research.
- Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.